Molnupiravir is a Direct Acting Anti-Viral drug which is taken orally as a treatment for COVID-19. That is, one would take the drug after getting infected. The drug would then begin to prevent virus replication and ultimately purge the virus from the body. The drug is produced by Merck $ Co, and in humanized mouse models, the use of molnupiravir as both a treatment and prophylaxis was found to reduce viral replication and pathogenesis. [1] This drug has been on the shelf for over four years,2 and had finished phase 1 trials when COVID-19 broke out. Currently, it is soon to complete phase 3 trails for the market.

In June 19th 2021 the President Biden administration announced it would make a drug deal with Merck and procure 1.7 million courses of the antiviral Molnupiravir to the US government for a cost of nearly $1.2 billion if approved by FDA or given an EUA. [4]

Under terms of agreement, BARDA collaborated with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army contracting Command on the $1.2 billion purchase agreement for the courses of MK-4482.

Contrast this purchase with the 4 billion the US Government will pay Pfizer, who, by the way, was going to be removed from the DOW just before the COVID-19 started7. A 3-billion-dollar deal with Moderna 8, and the 1 billion deal with J & J. The US Government spent a total of 8 billion dollars on the COVID vaccines. Thus, now we know why vaccines are important!

Molnupiravir seems to be an alternative to the current COVID needle injected GMO treatments. However, Molnupiravir is still a drug that manages the production mechanisms in the basic cell. That is, it inhibits proteins used by the virus in the sub cell level. In other words, the proteins the virus uses to reproduce itself. It is not an old fashion treatment that tricks the immune system into producing good antibodies that attack the virus. However, the best thing about Molnupiravir is no one needs to shallow the drug unless they are exposed or experience symptoms. That is, everyone in the country doesn't have to drink the Kool aide so to speak, which is a good idea since only 1 in 10 people will contact the virus. [5]

In closing, if the Biden administration is investing in this promising vaccine alternative and renowned virologist like Vincent Racaniello [6] are excited about its forecasted abilities, then why are we pushing for vaccine identity cards? why would the US Military be pushing mandatory vacccination with this drug on the horizon? Wouldn't a drug that can be used after exposure make vaccination a moot point. Knowing the FDA, it is unlikely they will deny the EUA or approval. Finally, The idea that the Federal Government is involved in the drug procurement and drug distribution, is extremely alarming to say the least.